Theralase Technologies Inc.
TLTFF
$0.12
$0.014.55%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 203.00K | 158.80K | 63.50K | 293.20K | 254.10K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 203.00K | 158.80K | 63.50K | 293.20K | 254.10K |
| Cost of Revenue | 87.70K | 73.10K | 54.30K | 105.20K | 106.90K |
| Gross Profit | 115.30K | 85.80K | 9.30K | 188.00K | 147.20K |
| SG&A Expenses | 379.60K | 369.40K | 434.20K | 382.80K | 366.30K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 943.60K | 863.70K | 1.10M | 954.40K | 950.20K |
| Operating Income | -740.60K | -704.90K | -1.04M | -661.20K | -696.10K |
| Income Before Tax | -734.70K | -688.10K | -1.03M | -655.90K | -687.40K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -734.70K | -688.10K | -1.03M | -655.90K | -687.40K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -734.70K | -688.10K | -1.03M | -655.90K | -687.40K |
| EBIT | -740.60K | -704.90K | -1.04M | -661.20K | -696.10K |
| EBITDA | -709.60K | -677.50K | -1.01M | -629.10K | -663.40K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 250.62M | 248.54M | 247.81M | 256.41M | 234.62M |
| Average Diluted Shares Outstanding | 250.62M | 248.54M | 247.81M | 256.41M | 234.62M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |